Rituximab as first line adjuvant in pemphigus: retrospective analysis of the long-term outcomes in a single center.

DOI
Publisher DOI
PubMed ID
29146127
Date Issued
2018-04
Publication Type
Article
Subject(s)
Subjects
Complete remission First line Pemphigus Relapse Rituximab
Language(s)
en
Author(s)
Vinay, Keshavamurthy
Amber, Kyle T
Additional Credits
Journal
Journal of the American Academy of Dermatology
Publisher
Elsevier
ISSN
0190-9622
Access(Rights)
open.access
Show full item